Between the Lines

Martin H. Voss, MD, and Moshe C. Ornstein, MD, review significant renal cell carcinoma research developments presented at ASCO 2024, highlighting data and insights poised to reshape the disease's treatment landscape.

Hematologic oncology specialists review recent data from the PERSEUS trial analyzing minimal residual disease in patients with newly diagnosed multiple myeloma who receive DARA-VRd.

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, review recent data from the MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma and have a discussion on evolving therapeutic practices.

Expert perspectives on the phase III MARIPOSA-2 trial results evaluating amivantamab-based regimens in EGFR-mutant NSCLC after osimertinib progression. The discussion covers efficacy, safety, clinical implications, and future directions featuring Martin Dietrich, MD; Ticiana Leal, MD, and Sandip P. Patel, MD.

Medical Oncologists Sandip Patel, MD and Helena Yu, MD discuss data from the HERTHENA-Lung01 trial investigating HER3-DXd in EGFR-mutated NSCLC and the evolving treatment landscape in NSCLC.

A panel of experts on multiple myeloma review data from the MonumenTAL-1 clinical trial investigating talquetamab and provide comprehensive insights on treating patients and managing adverse effects.

Marwan G. Fakih, MD, and Atif Hussein, MD, MMM, FACP, review data from the SUNLIGHT study and discuss their impact on the overall treatment landscape in metastatic colorectal cancer.

Expert perspectives on a recent clinical trial readout indirectly comparing acalabrutinib and zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Expert hematologist-oncologists review data from the MajesTEC-1 trial and discuss the optimal management of cytokine release syndrome in patients on therapy for relapsed/refractory multiple myeloma.

Key opinion leaders review recent data from the ASCO 2023 annual meeting surrounding the MonumenTAL-1 and RedirecTT-1 trials, considering their impact on the real-world management of relapsed/refractory multiple myeloma.

Toni Choueiri, MD, and Rohit Gosain, MD present 3-year follow-up data from the CheckMate 9ER trial, discussing a variety of outcomes concerning the use of nivolumab plus cabozantinib in patients with advanced renal cell carcinoma, and sharing clinical insights for community oncologists.

Joshua K. Sabari, MD, and Helena A. Yu, MD, discuss the evolving treatment landscape in non–small cell lung cancer for patients with EGFR exon 20 insertion mutations and results from a real-world study that may impact the field.

Nelson J. Chao, MD, MBA, and Michael Grunwald, MD review Acute Graft-Versus-Host Disease diagnosis and treatment before engaging with two REACH2 trial post hoc analyses, sharing clinical implications and key takeaways.

Expert hematologist-oncologists Thomas Leblanc, MD, and Bhumika Patel, MD, review clinical data behind the long-term use of tagraxofusp and share their own experience.

Expert oncologists Aditya Bardia, MD, MPH, and Alison Conlin, MD, review clinical data behind the use of sacituzumab govitecan in metastatic TNBC from the phase 3 ASCENT study.

Martin Dietrich, MD, PhD, Sara Tolaney, MD, MPH, and Gregory Vidal, MD, PhD review recent data from the TROPiCS-02 trial on sacituzumab govitecan and discuss the clinical implications of these findings.

Dr. Joseph Mikhael and Dr. Hakan Kaya review key efficacy and safety data for the combination of Selinexor, Carfilzomib and Dexamethasone in R/R MM and discuss optimal dosing and adverse event management strategies for selinexor.

Dr Joshua Richter and Dr Peter Forsberg review key trial data and dosing strategies for selinexor based combinations.

Expert hematologist-oncologists share insight on the E7438-G000-101 clinical trial and consider use of tazemetostat, an EZH2 inhibitor, in relapsed/refractory follicular lymphoma.

Expert oncologists review key data from the CRESTONE trial, which observed the safety and efficacy of seribantumab, an anti-HER3 IgG2 monoclonal antibody, in solid tumors with NRG1 fusions.

Shilpa Gupta, MD, and Vinit Makkar, MD, discuss the treatment patterns and disease management of locally advanced/metastatic urothelial carcinoma, with a focus on data from the US physician-based PARADIGM study.

Michael R. Bishop, MD, and Bruce B. Bank, MD, review results from the ELEVATE-RR noninferiority trial on acalabrutinib versus ibrutinib in CLL, and discuss the clinical implications of the findings.

Stacy A. Cohen, MD, and Mark Lewis, MD review results from the GALAXY study on circulating tumor DNA dynamics in CRC that were recently presented at ASCO GI 2022, and discuss the clinical implications of the findings.

Expert perspectives on recent updates in the use of proteasome inhibitors for patients with multiple myeloma.

A panel of oncologists reviews a publication by Motzer et al. (2021) on data from the CLEAR trial studying lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma treatment and discuss the clinical implications of the results.

Expert oncologists review safety/efficacy data behind mobocertinib, a small molecule tyrosine kinase inhibitor, in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.

Suzanne Fanning, DO, and Joshua Richter, MD, discuss clinical implications of a real-world study of ixazomib, lenalidomide, and dexamethasone compared with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Neeraj Agarwal, MD, and Simon Chowdhury, MD, review final results from the TITAN study of apalutamide in patients with mCSPC and discuss the clinical implications of the findings.

Experts discuss use of ponatinib in chronic myeloid leukemia and optimal dosing.